Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply. [electronic resource]
- The New England journal of medicine 11 2019
- 2076-2077 p. digital
Publication Type: Letter; Comment
1533-4406
10.1056/NEJMc1913157 doi
Diabetes Mellitus, Type 2 Glucagon-Like Peptides Humans Hypoglycemic Agents